Skip to main content
Fig. 64 (abstract P360). | Journal for ImmunoTherapy of Cancer

Fig. 64 (abstract P360).

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Fig. 64 (abstract P360).

Proper timing of IL-2 complex administration is necessary to induce CD8+ T cell responses. a C57BL/6 mice were injected with BiVax on day 0 combined with IL-2 complexCD122 (day 1, 2, and 3), IL-2 complexCD25 (day 1, 2, and 3) or IL-2Fc (day 1 to 4). The percentage of tetramer+ cells in CD8+ T cell or (b) CD44+ T cells in Trp1-tetramer- CD8+ T cells was examined in blood on day 7. c C57BL/6 mice received IL-2 complexCD122 on day 0, 2, and 4 and the number of CD44+ or CD122+ cells in spleen was examined on day 7. The picture of spleen after the treatment is shown. d C57BL/6 mice received TgTR1 cells (2000 cells/mouse) and BiVax. After 7 days, the expression of blood CD62L, CD44, and CD122 on activated TgTR1 cells were compared to naïve TgTR1 cells. b C57BL/6 mice were injected with BiVax on day 0 and 5. IL-2 complexCD122 or IL-2 complexCD25 was administered on day 5, 7, and 9. The percentages of tetramer+ cells in blood CD8+ T cells and (f) the numbers of tetramer+ cells in spleen on day 12 are shown. Results are presented as mean ± SD. (*p<0.05, n.s.: not significant)

Back to article page